Eltrombopag for Post Transplant Thrombocytopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 17, 2010

Primary Completion Date

April 4, 2018

Study Completion Date

April 4, 2018

Conditions
Thrombocytopenia
Interventions
DRUG

Eltrombopag

Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.

DRUG

Placebo

Once a day, orally for 8 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER